NASDAQ: RAPTRapt Therapeutics Inc Stock
$0.79-0.01 (-1.25%)
Updated Apr 17, 2025
RAPT Price
$0.79
Fair Value Price
N/A
Market Cap
$104.29M
52 Week Low
$0.75
52 Week High
$8.58
P/E
-0.25x
P/B
0.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$129.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.27
Operating Cash Flow
-$83M
Beta
1.66
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RAPT Overview
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RAPT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RAPT
Ranked#420 of 463
Ranked#420 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important RAPT news, forecast changes, insider trades & much more!
RAPT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RAPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RAPT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RAPT is good value based on its book value relative to its share price (0.55x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
RAPT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RAPT due diligence checks available for Premium users.
Valuation
RAPT fair value
Fair Value of RAPT stock based on Discounted Cash Flow (DCF)
Price
$0.79
Fair Value
$4.05
Undervalued by
80.51%
RAPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RAPT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
-177.72x
Market
27.98x
RAPT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
4.05x
RAPT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RAPT's financial health
Profit margin
Revenue
$0.0
Net Income
-$53.2M
Profit Margin
0%
RAPT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$240.3M
Liabilities
$50.4M
Debt to equity
0.27
RAPT's short-term assets ($235.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RAPT's short-term assets ($235.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RAPT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RAPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
-$843.0k
Financing
$143.1M
RAPT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RAPT vs Biotech Stocks
Rapt Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.